At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
PPARγ Agonist Treatment for Cocaine Dependence
In Brief
A Phase 2 clinical trial evaluating Pioglitazone, Placebo, and 2 other interventions for Cocaine Use Disorder and Alcohol Use Disorder. Completed, enrolled 30 participants across 1 site.
Detailed Summary
The purpose of this research study is to determine whether a medication called pioglitazone (trade name Actos) can reduce behavioral problems associated with cocaine use, improve brain structural changes associated with cocaine use and reduce cocaine craving and drug use in cocaine dependent patients.
Study Details
Timeline
Interventions
Subjects randomized to pioglitazone begin with a starting dose of 15 mg daily administered. The dose will be titrated up to 30mg on the second week and 45 mg on the third week of the study. Subjects will remain on 45 mg of pioglitazone until the end of week 12. At the end of week 12 the study medication will be discontinued.
Subjects randomized to placebo receive placebo capsules once daily across all twelve weeks of the study.
Cognitive-behavioral therapy 1 hour per week
Prize-based contingency management for attendance